Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice

Ley T, Miller C, Ding L, Raphael B, Mungall AJ RA, Hoadley K et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.

Bacher U, Haferlach T, Schnittger S, Kreipe H, Kroger N . Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol 2011; 153: 149–167.

Fatrai S, van Gosliga D, Han L, Daenen SM, Vellenga E, Schuringa JJ . KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways. J Biol Chem 2011; 286: 6061–6070.

Maher J, Baker D, Dibb N, Roberts I . Mutant ras promotes haemopoietic cell proliferation or differentiation in a cell-specific manner. Leukemia 1996; 10: 83–90.

Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157–163.

Mansur MB, Hassan R, Barbosa TC, Splendore A, Jotta PY, Yunes JA et al. Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia. BMC Cancer 2012; 12: 9.

Wiemels JL, Zhang Y, Chang J, Zheng S, Metayer C, Zhang L et al. RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia 2005; 19: 415–419.

Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45: 242–252.

Swan KA, Alberola-Ila J, Gross JA, Appleby MW, Forbush KA, Thomas JF et al. Involvement of p21ras distinguishes positive and negative selection in thymocytes. EMBO J 1995; 14: 276–285.

Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101: 597–602.

Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004; 113: 528–538.

Wahlstrom AM, Cutts BA, Liu M, Lindskog A, Karlsson C, Sjogren AK et al. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood 2008; 112: 1357–1365.

Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K et al. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Science Transl Med 2011; 3: 76ra27.

Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B et al. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci USA 2010; 107: 5106–5111.

Kindler T, Cornejo MG, Scholl C, Liu J, Leeman DS, Haydu JE et al. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood 2008; 112: 3373–3382.

Kong G, Du J, Liu Y, Meline B, Chang YI, Ranheim EA et al. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation. J Biol Chem 2013; 288: 18219–18227.

Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009; 7: e59.

Sjogren AK, Andersson KM, Khan O, Olofsson FJ, Karlsson C, Bergo MO . Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RAS-induced myeloproliferative disease. Leukemia 2011; 25: 186–189.

Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF et al. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 2009; 113: 1304–1314.

Kuhn R, Schwenk F, Aguet M, Rajewsky K . Inducible gene targeting in mice. Science 1995; 269: 1427–1429.

Dumortier A, Durham AD, Di Piazza M, Vauclair S, Koch U, Ferrand G et al. Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of Notch signaling in the murine skin. PLoS One 2010; 5: e9258.

Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852–857.

Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243–3248.

O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 2006; 107: 781–785.

Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K . Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood 2006; 108: 2041–2044.

Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269–271.

Sun L, Heerema N, Crotty L, Wu X, Navara C, Vassilev A et al. Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci U SA 1999; 96: 680–685.

Du J, Liu Y, Meline B, Kong G, Tan LX, Lo JC et al. Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals. Leukemia 2013; 27: 754–757.

Vartanian S, Bentley C, Brauer MJ, Li L, Shirasawa S, Sasazuki T et al. Identification of mutant KRas-dependent phenotypes using a panel of isogenic cell lines. J Biol Chem 2013; 288: 2403–2413.

Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 2001; 29: 25–33.

Matallanas D, Romano D, Al-Mulla F, O'Neill E, Al-Ali W, Crespo P et al. Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell 2011; 44: 893–906.

Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L et al. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 2014; 25: 243–256.

Romero F, Martinez AC, Camonis J, Rebollo A . Aiolos transcription factor controls cell death in T cells by regulating Bcl-2 expression and its cellular localization. EMBO J 1999; 18: 3419–3430.